GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hubei Hongyuan Pharmaceutical Technology Co Ltd (SZSE:301246) » Definitions » Long-Term Capital Lease Obligation

Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Long-Term Capital Lease Obligation : ¥8 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Hubei Hongyuan Pharmaceutical Technology Co Long-Term Capital Lease Obligation?

Hubei Hongyuan Pharmaceutical Technology Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥8 Mil.

Hubei Hongyuan Pharmaceutical Technology Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥9 Mil) to Dec. 2023 (¥7 Mil) but then increased from Dec. 2023 (¥7 Mil) to Mar. 2024 (¥8 Mil).

Hubei Hongyuan Pharmaceutical Technology Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥8 Mil) to Dec. 2022 (¥8 Mil) and declined from Dec. 2022 (¥8 Mil) to Dec. 2023 (¥7 Mil).


Hubei Hongyuan Pharmaceutical Technology Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Hubei Hongyuan Pharmaceutical Technology Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Hongyuan Pharmaceutical Technology Co Long-Term Capital Lease Obligation Chart

Hubei Hongyuan Pharmaceutical Technology Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.12 8.23 8.19 6.90

Hubei Hongyuan Pharmaceutical Technology Co Quarterly Data
Jun15 Dec15 Jun16 Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.85 8.37 8.95 6.90 7.59

Hubei Hongyuan Pharmaceutical Technology Co  (SZSE:301246) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Hubei Hongyuan Pharmaceutical Technology Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Hubei Hongyuan Pharmaceutical Technology Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Hongyuan Road, Economic Development Zone, Luotian County, Hubei Province, Fengshan Town, CHN, 438600
Hubei Hongyuan Pharmaceutical Technology Co Ltd is engaged in the research and development, production and sales of organic chemical raw materials, pharmaceutical intermediates, raw materials and pharmaceutical preparations.

Hubei Hongyuan Pharmaceutical Technology Co (SZSE:301246) Headlines

No Headlines